Bausch + Lomb Q4 Earnings Review: Still A Buy, With Some Caveats
Source: SeekingAlpha
2026-02-19 14:54:45 ET
Investment Overview
Bausch + Lomb Corporation ( BLCO ), a leading global eye health specialist and marketer and seller of ~400 products in total (source: Q3 2025 10-Q filing ), announced its Q4 and full-year earnings on February 18th....
Read the full article on Seeking Alpha
For further details see:
Bausch + Lomb Q4 Earnings Review: Still A Buy, With Some Caveats
Bausch + Lomb Corporation
NASDAQ: BLCO
BLCO Trading
0.63% G/L:
$17.46 Last:
148,048 Volume:
$17.28 Open:
BLCO Latest News
February 24, 2026 07:00:00 am
Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®
February 18, 2026 06:58:00 am
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance
BLCO Stock Data
$6,074,354,796
39,385,904
0.1%
19
N/A
Medical Equipment & Supplies
Healthcare
CA
Vaughan
